Jonathan Licht, MD, Johanna Dobe Professor and Chief of Hematology and Medical Oncology at the
Feinberg School of Medicine, and Associate Director for Clinical Sciences Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, is one of four researchers recently awarded a
grant from the Leukemia & Lymphoma Society (LLS) through its Marshall A. Lichtman Specialized Center
of Research (SCOR). Licht's grant totals $6.25 million over five years.
The SCOR program funds teams of researchers representing different disciplines who are engaged in
collaborative efforts to discover new approaches to treat patients with hematological malignancies.
Along with a distinguished group of co-investigators at Rockefeller University, Weill Cornell Medical
College, Memorial Sloan Kettering Cancer Center, and the University of Michigan, Licht studies aberrant
epigenetic regulation in leukemia, lymphoma, and myeloma.
"Our goal is to have a deeper understanding of how genes are turned on and off by epigenetic, that is non-inherited modifications of DNA and its surrounding proteins. We will determine how mutations that occur in blood cancers lead to patterns of abnormal gene regulation and how we can reverse these abnormal patterns with new therapeutic agents," Licht said.
Over the past five years, the group has published several papers in high impact journals such as Blood
and Cancer Cell.